Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present TapImmune, Inc. (OTC: TPIV).

Full DD Report for TPIV

You must become a subscriber to view this report.


Recent News from (OTC: TPIV)

TapImmune (TPIV) To Merge With Marker Therapeutics - Slideshow
The following slide deck was published by TapImmune, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: May, 16 2018 14:32
TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform
JACKSONVILLE, Fla. , May 16, 2018 /PRNewswire/ --  TapImmune Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company, today announced that it has assembled a Scientific Advisory Board (SAB) composed of leading experts in the field of immuno-oncology and cell therapy and that w...
Source: PR Newswire
Date: May, 16 2018 06:30
TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker Therapeutics
JACKSONVILLE, Fla. , May 15, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company, today announced that it will host a breakfast meeting for analysts and investors this Thursday, May 17, 2018 , at the Blackrock Hotel in Chicago . During ...
Source: PR Newswire
Date: May, 15 2018 16:05
TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno-Oncology Platform
JACKSONVILLE, Fla. , May 15, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV) ("TapImmune") today announced that it has entered into a definitive merger agreement to acquire Marker Therapeutics, Inc. ("Marker"), a privately-held clinical-stage developer of a transformative, non-geneti...
Source: PR Newswire
Date: May, 15 2018 05:32
TapImmune to Present at 2018 NYC Oncology Investor Conference
JACKSONVILLE, Fla. , May 7, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that its President and CEO, Peter Hoang , will give a company presentation at t...
Source: PR Newswire
Date: May, 07 2018 06:30
TapImmune to Present at 2018 Disruptive Growth & Healthcare Conference
JACKSONVILLE, Fla. , May 1, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today announced that its President and CEO, Peter Hoang , will participate in a panel discussion a...
Source: PR Newswire
Date: May, 01 2018 06:30
Blog Exposure - GTx Completed Patient Enrollment Several Months Ahead in the Phase-2 Clinical Trial of Enobosarm in SUI
Stock Monitor: TapImmune Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 11, 2018 / Active-Investors.com has just released a free research report on GTx, Inc. (NASDAQ: GTXI ). If you want access to this report all you need to do is sign up now by clicking the following link ...
Source: ACCESSWIRE IA
Date: April, 11 2018 07:10
TapImmune's (TPIV) CEO Peter Hoang on Q4 2017 Results - Earnings Call Transcript
TapImmune Inc. (TPIV) Q4 2017 Results Conference Call April 05, 2018 04:30 PM ET Executives Josh Drumm - IR Peter Hoang - President and Chief Executive Officer Dr. Richard Kenney - Chief Medical Officer Dr. Michael Loiacono - Chief Financial Officer Analysts Steve Brozak ...
Source: SeekingAlpha
Date: April, 05 2018 20:19
TapImmune with Q4 update and conference call
Recent developments include the publication of long-term immune response and progression-free survival data from completed Phase 1 clinical study of TPIV200, and the beginning of dosing for the 280-patient, grant-funded Phase 2 study of TPIV200 in women with advanced TNBC. More n...
Source: SeekingAlpha
Date: April, 05 2018 16:25
TapImmune Provides Fourth Quarter and Year-End 2017 Corporate and Clinical Update
JACKSONVILLE, Fla. , April 5, 2018 /PRNewswire/ -- Recent Corporate and Clinical Developments: Published long-term immune response and progression-free survival data from completed Phase 1 clinical study of TPIV200 Commenced dosing in 280-patient, grant-funded Phase 2 st...
Source: PR Newswire
Date: April, 05 2018 16:05

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-167.807.717.9357.6080,932
2018-08-158.097.78888.09997.5093,706
2018-08-147.708.218.257.7060,768
2018-08-137.517.718.0377.3096,243
2018-08-108.507.638.507.57502,303

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2016-11-076,99423,25130.0804Cover
2016-11-045,85720,53228.5262Cover
2016-11-032,6769,26128.8954Cover
2016-11-021802,1118.5268Cover
2016-11-013,3457,22846.2784Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on TPIV.


About TapImmune, Inc. (OTC: TPIV)

Logo for TapImmune, Inc. (OTC: TPIV)

Cancer and viral disease immunotherapy products R amp D company

 

 

 

Current Management

  • Glynn Wilson / CEO
  • John Bonfiglio / President, COO
    • Dr. Bonfiglio has broad experience in corporate strategy and financing, market interactions and business development. He was most recently President and CEO of Oragenics where he refocused the company and raised over million dollars in the public markets while positioning the company for a successful relisting on the NYSE: MKT stock exchange. He was formerly President and CEO of Argos Therapeutics where he raised over million dollars for the Company and led the company in a successful Phase study in renal cell carcinoma. As President and CEO of the Immune Response Corporation he was responsible for turning the Company around through improved therapeutic focus, capital raising over million and improved investor relations resulting in a significant increase in stock price and shareholder value. John was also President and CEO of Peregrine Pharmaceuticals and Director of Business Development at Baxter Healthcare Corporation s Immunotherapy Division. John has a Ph.D from the University of California, San Diego, and an MBA from Pepperdine University. As a result of his appointment, the number of our board directors has increased from four to five.
  • Michael Joseph Loiacono / CFO, Chief Accounting Officer, Secretary, Treasurer
  • Glynn Wilson / Chairman
  • John Bonfiglio / Dr. Bonfiglio has broad experience in corporate strategy and financing, market interactions and business development. He was most recently President and CEO of Oragenics where he refocused the company and raised over million dollars in the public markets while positioning the company for a successful relisting on the NYSE: MKT stock exchange. He was formerly President and CEO of Argos Therapeutics where he raised over million dollars for the Company and led the company in a successful Phase study in renal cell carcinoma. As President and CEO of the Immune Response Corporation he was responsible for turning the Company around through improved therapeutic focus, capital raising over million and improved investor relations resulting in a significant increase in stock price and shareholder value. John was also President and CEO of Peregrine Pharmaceuticals and Director of Business Development at Baxter Healthcare Corporation s Immunotherapy Division. John has a Ph.D from the University of California, San Diego, and an MBA from Pepperdine University. As a result of his appointment, the number of our board directors has increased from four to five.
  • Sherry Grisewood /
  • David LaskowPooley /
  • Mark Reddish /
  • Frederick G. Wasserman / Mr. Wasserman is a business executive with over years of business experience, having served at various companies in roles including Chief Executive Officer, President, Chief Operating Officer and Chief Financial Officer. He is currently the President of FGW Partners LLC, Pennington, NJ, where he has been employed since . He currently serves on the boards of directors of several public companies. Mr. Wasserman was employed as a certified public accountant from to . He earned a Bachelor of Science degree from The Wharton School at The University of Pennsylvania in .

Current Share Structure

  • Market Cap: $37,308,262 - 03/09/2018
  • Authorized: 41,666,667 - 09/16/2016
  • Issue and Outstanding: 10,539,057 - 11/01/2017
  • Float: 6,759,749 - 09/16/2016

 


Recent Filings from (OTC: TPIV)

Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: May, 16 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: May, 15 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Filing by person(s) reporting owned shares of common stock in a public company >5%
Filing Type: SC 13DFiling Source: edgar
Filing Date: April, 04 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 23 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: March, 23 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 14 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: January, 26 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: December, 29 2017

 

 


Daily Technical Chart for (OTC: TPIV)

Daily Technical Chart for (OTC: TPIV)


Stay tuned for daily updates and more on (OTC: TPIV)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: TPIV)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in TPIV is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of TPIV and does not buy, sell, or trade any shares of TPIV. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/